Novo presents low-dose CagriSema data showing competitiveness ahead of approval decision
read at Endpoints ↗Positive readoutPositive
Novo used its capital markets day in London to unveil new low-dose data for its experimental metabolic therapy CagriSema.
The data indicated that CagriSema performed comparably to Eli Lilly's Mounjaro when both were administered at reduced doses, suggesting a potential competitive edge in the obesity/diabetes space.
The company said the results arrive as regulators consider a pending approval decision, and the findings could influence the upcoming review.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo offers low-dose CagriSema data as approval decision looms”
read at Endpoints ↗78 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that